Diflomotecan

Drug Profile

Diflomotecan

Alternative Names: BN-80915; R1536

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Biomeasure Inc
  • Developer Ipsen
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Small cell lung cancer

Most Recent Events

  • 29 Dec 2010 Discontinued - Phase-II for Small cell lung cancer in France (PO)
  • 29 Dec 2010 Discontinued - Phase-II for Small cell lung cancer in Netherlands (PO)
  • 29 Dec 2010 Discontinued - Phase-II for Small cell lung cancer in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top